Sedana Medical AB (FRA:7D2A)

Q3 2025 Sedana Medical AB (publ) Earnings Call Transcript

Oct 24, 2025 / 11:30 AM GMT

Release Date Price: €1.12 (+1.26%)

Transcript

Key Points

Positve

Sedana Medical AB (FRA:7D2A) achieved a positive EBITDA year-to-date, demonstrating effective cost management despite lower-than-expected sales.
The company reported an 18% year-to-date sales growth, with 12% being organic, indicating strong underlying business performance.
The acquisition of the main supplier in Malaysia has started to positively impact the gross margin.
Sedana Medical AB (FRA:7D2A) is on track with its US market entry strategy, with successful clinical trials and an early access program in place.
The company has a strong presence in Europe, with significant growth in markets like Spain, contributing to over a third of core business sales.

Negative

Sales in Q3 were lower than expected, primarily due to seasonal swings and fewer ICU patients with respiratory issues.
Germany, a key market, saw a 9% decline in net sales due to lower hospitalization rates for respiratory infections.
The UK market faced challenges due to temporary staff absence, impacting field presence and growth.
The company is experiencing exchange rate headwinds, which have affected financial performance.
There is uncertainty regarding the timeline for US market approval, with potential delays depending on FDA feedback.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SEDANA.ST - Sedana Medical AB (publ)
Q3 2025 Sedana Medical AB (publ) Earnings Call
Oct 24, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone. Welcome to today's Finwire webcast presentation with the Sedona Medical.

With us presenting it today, we have the CEO Johannesto, CEO Johann Spetz, and CEO Peter Sakchi.

We'll do a Q&A after the presentation. You can either type in your questions using inform to write, or if you're calling in, and would like to a question, please press 9 to raise your hand and 6 don't mute when you get the word.

And with that said, please go ahead with your presentation.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you for the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.